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ABSTRACT
Introduction Asthma affects millions of children 
worldwide—1.1 million children in the UK. Asthma 
symptoms cannot be cured but can be controlled with 
low- dose inhaled corticosteroids (ICSs) in the majority 
of individuals. Treatment with a low- dose ICS, however, 
fails to control asthma symptoms in around 10%–15% 
of children and this places the individual at increased 
risk for an asthma attack. At present, there is no clear 
preferred treatment option for a child whose asthma is not 
controlled by low- dose ICS and international guidelines 
currently recommend at least three treatment options. 
Herein, we propose a systematic review and individual 
participant data network meta- analysis (IPD- NMA) aiming 
to synthesise all available published and unpublished 
evidence from randomised controlled trials (RCTs) to 
establish the clinical effectiveness of pharmacological 
treatments in children and adolescents with uncontrolled 
asthma on ICS and help to make evidence- informed 
treatment choices. This will be used to parameterise 
a Markov- based economic model to assess the cost- 
effectiveness of alternative treatment options in order to 
inform decisions in the context of drug formularies and 
clinical guidelines.
Methods and analysis We will search in MEDLINE, 
the Cochrane Library, the Cochrane Central Register of 
Controlled Trials (CENTRAL), Embase, NICE Technology 
Appraisals and the National Institute for Health Research 
(NIHR) Health Technology Assessment series for RCTs 
of interventions in patients with uncontrolled asthma on 
ICS. All studies where children and adolescents were 
eligible for inclusion will be considered, and authors or 
sponsors will be contacted to request IPD on patients aged 
<18. The reference lists of existing clinical guidelines, 
along with included studies and relevant reviews, will be 
checked to identify further relevant studies. Unpublished 
studies will be located by searching across a range of 
clinical trial registries, including internal trial registers for 
pharmaceutical companies. All studies will be appraised 
for inclusion against predefined inclusion and exclusion 
criteria by two independent reviewers with disagreements 
resolved through discussion with a third reviewer. We will 
perform an IPD- NMA—eventually supplemented with 
aggregate data for the RCTs without IPD—to establish 
both the probability that a treatment is best and the 
probability that a particular treatment is most likely to be 
effective for a specific profile of the patient. The IPD- NMA 
will be performed for each outcome variable within a 
Bayesian framework, using the WinBUGS software. Also, 
potential patient- level characteristics that may modify 
treatment effects will be explored, which represents one of 
the strengths of this study.
Ethics and dissemination The Committee on Research 
Ethics, University of Liverpool, has confirmed that ethics 
Strengths and limitations of this study
 ► This study will be the most comprehensive synthesis 
of interventional studies of children and adolescents 
with uncontrolled asthma on inhaled corticosteroid.
 ► It will be able to establish the most clinically and 
cost- effective step- up therapy for asthma, also con-
sidering those treatments where no head- to- head 
comparison exists, providing evidence to make in-
formed treatment choices.
 ► It will be able to evaluate the influence of patient- 
level characteristics on treatment effect.
 ► It will provide an assessment of the incremental cost 
per quality- adjusted life- year gained of treatment 
options, from the perspective of the National Health 
Service and personal social services.
 ► Individual participant data may not be available from 
all eligible randomised controlled trials and integra-
tion with aggregate data may be needed.  on F









pen: first published as 10.1136/bm





2 Cividini S, et al. BMJ Open 2021;11:e040528. doi:10.1136/bmjopen-2020-040528
Open access 
review is not required. The dissemination plan consists of publishing the 
results in an open- access medical journal, a plain- language summary 
available for parents and children, dissemination via local, national 
and international meetings and conferences and the press offices of 
our Higher Education Institutions (HEIs). A synopsis of results will be 
disseminated to NICE and British Thoracic Society/Scottish Intercollegiate 
Guidelines Network (SIGN) as highly relevant to future clinical guideline 
updates.
PROSPERO registration number CRD42019127599.
INTRODUCTION
Rationale
Recent epidemiological data show that an always- 
increasing number of people of all age groups worldwide, 
among that millions of children and adolescents, are 
affected by asthma with a notable social and economic 
burden for health systems.1 Asthma remains a common 
medical condition affecting over one million children in 
the UK, one of the highest prevalence rates worldwide.2 3 
Asthma is characterised by symptoms of wheeze, breath-
lessness, chest tightness and cough and can affect the 
child’s quality of life (QoL) by limiting daily activities and 
causing acute attacks. In the UK, it was estimated that one 
child is admitted to the hospital every 20 min because of 
an asthma attack.2
The British guideline4 5 on the management of asthma 
recommends that, following a diagnosis of asthma in a 
child, a stepwise approach to treatment should be taken. 
The initial level of treatment is a low- dose inhaled corti-
costeroid (ICS) to prevent symptoms plus a short acting 
β2- adrenoceptor agonist (SABA) to relieve symptoms. 
However, treatment with a low- dose ICS fails to control 
asthma symptoms in around 10%–15% of children.6 If 
asthma remains uncontrolled, a series of further steps are 
followed consisting of a treatment step- up by including 
add- on preventer therapies such as long- acting β2- 
adrenoceptor agonists (LABAs) or leukotriene receptor 
antagonists (LTRAs), increasing the dose of ICS or adding 
sustained- release (SR) theophylline.1 4 5
Choosing the best step- up treatment thus becomes a 
crucial decision to prevent exacerbations and to avoid poor 
asthma control, also improving the QoL of patients and 
their families and optimising the use of National Health 
Service (NHS) resources.7–12 At present, no clear prefer-
ential option for initial step- up exists, and the decision- 
making process about treatment choices is mainly based 
on clinicians’ preferences and not on evidence- based 
practice. Moreover, there is substantial heterogeneity 
among individuals in the treatment response.13 14
A recent Cochrane review15 comprising of 33 trials with 
6381 children demonstrated that adding LABAs to ICSs 
was not associated with a significant decrease in the rate 
of exacerbations requiring systemic steroids but was supe-
rior for improving lung function (eg, forced expiratory 
volume in 1 s (FEV1) and peak expiratory flow (PEF)), 
compared with the same or higher doses of ICS. No statis-
tically significant group difference in hospital admissions 
was found. Notwithstanding, because of a trend towards 
increased risk of hospital admission with LABA inde-
pendently of ICS dose, the authors advised further moni-
toring of treatment.15
Another Cochrane review16 published in 2013 found 
that adding LABAs to ICSs was associated with no statis-
tically significant reduction neither of the use of oral 
corticosteroids (OCS) as rescue nor hospital admissions 
compared with the same or an increased dose of ICS. 
Evidence was based only on four trials with 559 children 
and adolescents having mild- to- moderate asthma.16 The 
authors cautioned that the lack of paediatric trials, the 
absence of data on preschoolers and the variability in the 
reporting of relevant clinical outcomes was a limit for 
firm conclusions regarding this comparison.16
Two network meta- analyses (NMAs), analysing 
published randomised controlled trial (RCT) aggregate- 
level data for children with uncontrolled asthma, have 
already been conducted,17 18 but the evidence from these 
analyses has important limitations. The considerable 
variation in and the incomplete reporting of outcome 
measurements across RCTs prevented a formal NMA 
and assessment of relative efficacies of treatments in 
one NMA of 23 RCTs (4129 patients).18 In 2015, Zhao 
et al17 conducted a formal NMA consisting of 35 RCTs 
with 12 010 children. These authors suggested that 
combined ICS and LABA treatments were most effective 
in preventing exacerbations and that treatments with 
medium- dose or high- dose ICS, combined ICS/LTRA 
and low- dose ICS seem to be equally effective.17 However, 
the analysis has limitations as the authors excluded 70 
relevant RCTs because publications of these RCTs did 
not provide data about ‘exacerbations’ or ‘symptom- free 
days’. Outcome reporting bias19 is, therefore, a severe 
threat to the validity of their results if the excluded studies 
had selectively reported results based on the statistical 
significance of their findings. Moreover, a series of other 
issues make the interpretation and generalisability of the 
results of this NMA difficult. There is a lack of complete 
overlapping of the included studies compared with the 
previous Cochrane reviews15 16 and previous planned 
NMA18—only seven RCTs are in common across the two 
NMAs.17 18 Two other weak points are represented by the 
lack of analyses focussing on outcomes of importance and 
relevance to patients and the lack of analyses comparing 
different drugs (ICS, LABA, LTRA), doses and types of 
inhalation devices within ICS and LABA classes. We have 
also included tiotropium in the search algorithm as a 
long- acting muscarinic antagonists (LAMA), but we are 
not confident of finding sufficient studies.
Several RCTs have compared two alternative step- up 
options head to head, but only a few individual trials have 
analysed more than two classes head to head. The Best 
Add- on Therapy Giving Effective Responses (BADGER) 
trial14 randomised 182 children and adolescents with 
uncontrolled asthma on fluticasone to receive each of 
the following therapies: ‘ICS step- up’, ‘LABA step- up’ 
and ‘LTRA step- up’, obtaining differential responses 
to every step- up treatment. ‘LABA step- up’ showed 
 on F
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significantly more likely to provide the ‘best’ response; 
yet, many patients better replied with ‘ICS or LTRA step- 
up’ suggesting that for some patients, these treatments 
may be preferred.14 Overall, results from BADGER trial 
were heterogeneous and a 16- week follow- up may not be 
sufficient.
The Management of Asthma in School age Children 
On Therapy (MASCOT) trial20 randomised children aged 
6–14 to fluticasone plus placebo, fluticasone/salmeterol 
plus placebo and fluticasone plus montelukast. However, 
this RCT failed to recruit an adequate number of patients 
due to significant organisational challenges, issues of 
accessing patients from primary care and changes in 
prescribing habits during the trial. These challenges limit 
the potential success of similar future clinical trials and 
recommendations have been made for the use of alter-
native study designs20 21 to compare alternative step- up 
treatments.
There is thus an urgent need for a novel approach to 
be taken to synthesise all of the available evidence using 
robust, unbiased methods, also including unpublished 
data. A key strength of the EstablishINg the best STEp- up 
treatments for children with uncontrolled asthma despite 
INhaled corticosteroids (EINSTEIN) analysis will be 
the assessment of individual patient- level characteristics 
in modifying the patient’s response to treatment. No 
study has previously considered this aspect, although 
it represents a crucial clinical step in evaluating treat-
ment efficacy. Furthermore, an economic analysis of the 
treatment options will provide evidence on their cost- 
effectiveness from the perspective of the NHS in the UK. 
Results from the EINSTEIN Study will provide clinicians 
and patients with accessible, high- quality, patient- relevant 
information to help make evidence- informed treatment 
choices. Earlier identification of the best step- up treat-
ment for a particular child could have a significant impact 
on children’s lives with more extensive benefits to society 
and the NHS.
Objectives
Our research objective is to establish the best treatment 
option for patients younger than 18 whose asthma symp-
toms are uncontrolled by low–medium dose ICS. To this 
goal, the EINSTEIN Study will identify and synthesise 
all available evidence from RCTs to establish the effec-
tiveness of pharmacological treatments in children and 
adolescents aged <18 having poor asthma control on ICS. 
The study will also investigate the modifiers of treatment 
effect (eg, age, ethnicity, asthmatic phenotype) to opti-
mise a targeted therapy and maximise patients’ informed 
choice of treatment. The economic analysis will estimate 
the cost- effectiveness of treatments in terms of their incre-
mental costs per quality- adjusted life- year (QALY) gained.
Specifically, we aim to:
1. Conduct a systematic review to identify relevant RCTs 
of treatment with children and adolescents whose asth-
ma remains uncontrolled despite ICS use.
2. Collect individual participant data (IPD) from all eli-
gible trials.
3. Carry out an NMA of IPD to identify the most effective 
treatment.
4. Identify modifiers of treatment effect to establish 
which patients respond better to each treatment.
5. Develop an economic model to estimate the incremen-
tal cost per QALY gained of treatment options, from 
the perspective of the NHS and Personal Social Ser-
vices.
6. Identify remaining uncertainties formulating recom-




The Preferred Reporting Items for Systematic Reviews 
and Meta- Analysis Protocols (PRISMA- P) guidelines 22 
have guided the drafting of this protocol.
Eligibility criteria
For inclusion in the EINSTEIN Study, we will select studies 
according to the criteria outlined below.
Study designs
We will include parallel and cross- over RCTs, of any 
duration, using any level of blinding and comparing at 
least one of the health technologies of interest. All RCTs 
meeting our inclusion criteria will be included irrespec-
tive of the outcomes reported in the publication, to 
reduce the potential for outcome reporting bias.
Participants
We will focus on children (<12 years) and adolescents 
(12–17 years) of any ethnicity with poor asthma control 
on ICS before randomisation as defined by the study 
protocol. We will include studies with mixed- age groups in 
which children and adolescents were eligible because we 
will contact authors concerning specific data on patients 
aged <18. Patients aged ≥18, or with stable asthma as 
defined by the study authors, or using an asthma medica-
tion other than ICS, or an ICS with an add- on active (eg, 
ICS/LABA) as treatment regimen before randomisation 
will not be considered. Participants using any dose ICS at 
randomisation will be eligible for inclusion.
Interventions
We will consider as eligible all studies where children 
and adolescents were randomised to at least one of the 
following treatments:
 ► ICSs, alone or in combination with other treatments—
beclometasone dipropionate; ciclesonide; fluticasone 
propionate; fluticasone furoate; budesonide and 
mometasone.
 ► LABAs—formoterol; salmeterol and vilanterol.
 ► LTRAs—zafirlukast and montelukast.
 ► Theophylline.
 on F
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Any dose of preventer treatment—oral or inhaled, and 
any inhaler devices (pressurised metered- dose inhaler, dry 
powder inhaler, combination inhaler)—will be consid-
ered. Presence or absence of spacer devices will be noted.
We will not consider studies with participants 
randomised to any asthma medication other than those 
listed in the inclusion criteria.
Comparators
For both primary and secondary outcomes—if not spec-
ified otherwise—patient outcomes will be compared at 
two levels, namely among:
1. Every class of treatment—ICS (alone or with add- on 
actives), LABA, LTRA, theophylline and placebo. For 
ICS, we will distinguish between low, medium and 
high doses as defined in Global Initiative for Asthma 
(GINA)11—(table 1 and figure 1).
2. Every drugs within every class of treatment—be-
clometasone dipropionate; ciclesonide; fluticasone 
propionate; fluticasone furoate; budesonide; mometa-
sone; formoterol; salmeterol; vilanterol; zafirlukast; 
montelukast; theophylline and placebo.
Moreover, we will explore hierarchical models that 
consider both classes of treatments and actives with inter-
actions of covariates. Healthy controls will not be consid-
ered as an appropriate reference group.
Outcomes
Review outcomes will include the outcomes identified as 
important to healthcare practitioners and patients during 
the development of a core outcome set for trials in chil-
dren with asthma.23 24
Primary outcomes
 ► Exacerbations as defined by European Respiratory 
Society (ERS)/American Thoracic Society (ATS).24
 ► Asthma control measured by a validated test (eg, 
asthma control test (ACT),25 asthma control question-
naire (ACQ),26–29 other).
Secondary outcomes
 ► Symptoms/symptom score.
 ► QoL.
 ► Mortality—although rare, this is an important 
outcome for parents.
 ► Physiological outcomes (eg, FEV1 and bronchial 
responsiveness).
 ► Adverse effects (AEs)—including growth and with-
drawals due to AEs.
 ► Hospital admissions.
 ► Total healthcare costs (obtained by the sum–product 
of item of resource use and their unit cost), resource 
use and utility outcomes to inform the economic 
model.
Timing
Studies will be selected for inclusion independently of the 
length of follow- up of outcomes.
Setting
There will be no restrictions by type of setting.
Table 1 Estimated clinical comparability daily doses (µg) of 
inhaled corticosteroids






















Mometasone furoate 110 (≥4 
years)
N.A. N.A.
Ciclesonide N.A. N.A. N.A.
6–11- year old (children)










Budesonide (DPI) 100–200 >200–400 >400
Budesonide (nebules) 250–500 >500–1000 >1000










Mometasone furoate 110 ≥220-<440 ≥440
≥12- year old (adults and adolescents)










Budesonide (DPI) 200–400 >400–800 >800










Mometasone furoate 110–220 >220–440 >440
CFC, chlorofluorocarbon propellant (no longer used; included 
for comparison with older literature); DPI, dry powder inhaler; 
HFA, hydrofluoroalkane propellant; N.A, not applicable; pMDI, 
pressurized metered dose inhaler.
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Figure 1 Treatment step- up for asthmatic patients according to age group. Adapted from Global Initiative for Asthma.1 ICS, 
inhaled corticosteroid; IL, interleukin; LABA, long- acting β2- adrenoceptor agonist; LTRA, leukotriene receptor antagonist; OCS, 
oral corticosteroids; SABA, short- acting β.2- adrenoceptor agonist.
 on F
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Language
We will include only articles reported in the English 
language.
Information sources and search strategy
Our search strategy will identify published and unpublished 
studies and builds on previously published search strategies 
for aggregate data NMAs17 18 and Cochrane reviews15 16 30–32 
(see online supplemental file 1; for example, MEDLINE 
search). The search strategies will run from 2014 onwards 
only. From inception to 2013, we will consider as exhaus-
tive the searches already carried out for the meta- analyses 
and Cochrane reviews mentioned above,15–18 30–32 and we 
will retrieve all the corresponding studies.
We will search MEDLINE, the Cochrane Library, the 
Cochrane Central Register of Controlled Trials, Embase, 
National Institute for Health and Care Excellence (NICE) 
Technology Appraisals and the NIHR Health Technology 
Assessment series using relevant search terms. We will also 
scan the reference list of included studies and relevant 
reviews along with the reference lists of existing clinical 
guidelines such as the British Thoracic Society (BTS) 
guideline4 5 and GINA.1
For unpublished studies, we will search a range of 
clinical trial registries enclosed inside the WHO ‘Inter-
national Clinical Trials Registry Platform’ search portal 
(including  clinicaltrials. gov and International Standard 
Randomised Controlled Trial Number (ISRCTN)) and 
conference abstracts (eg, European Respiratory Society 
and American Thoracic Society).
We will also search internal clinical trial registers for 
pharmaceutical companies that manufacture health 
technologies of interest (eg, GSK, AstraZeneca, Novartis, 
Merck).
We will limit the search to English language articles, 
and we will verify that RCTs have included participants 
aged <18 as a subset.
Study records
Data management
Studies identified for screening of abstracts and full- text 
articles will be managed within Covidence (https://www. 
covidence. org/ home), a systematic review management 
tool.
Selection process
All studies will be screened and assessed for inclusion by 
two independent reviewers (SC and KR) with disagree-
ments resolved through discussion with a third reviewer 
(IS). To minimise the impact of selective outcome 
reporting, we will include all RCTs meeting our inclusion 
criteria irrespective of the outcome(s) reported in the 
publication. The authors will thus be contacted to ask for 
information and the IPD for all outcomes relevant to the 
review.
Data collection process
The first author, or sponsor, of each included trial will 
be approached and asked to supply anonymised IPD, 
metadata and relevant documentation33 (protocol and 
blank case report forms) from the respective trial, either 
through direct contact or through data sharing portals 
such as  clin ical stud ydat arequest. com, where relevant.
Before starting the quantitative synthesis, we will 
conduct a set of standard quality and consistency checks 
on the provided data. This will involve crosschecks by 
reanalysing IPD against previously published results to 
highlight inconsistencies or possible errors. Any queries 
will be raised with the original trialists wherever possible. 
Data will be cleaned and standardised to allow pooling 
and subsequent analyses of the data.
Data items
The data requested from each clinical trial will include 
at least:
 ► Baseline characteristics—age; sex; ethnicity; eczema; 
height; weight; baseline severity; baseline PEF rate 
(PEFR) and FEV1. Where available, we will also collect 
other variables such as age at asthma diagnosis; 
asthma- related hospitalisation and exacerbation 
history; allergic sensitisation; parental asthma and 
objective indicators of asthma such as bronchodilator 
reversibility or methacholine PC20.
 ► The date of randomisation and dates of follow- up 
visits/interval between randomisation and follow- up.
 ► Treatment details including inhalation device and 
dose.
 ► Adherence data if available.
 ► Data for the review outcomes along with details of 
their definitions and measurement tools used—symp-
toms; exacerbations; asthma control; mortality; QoL; 
growth; physiological outcomes: PEFR and FEV1 and 
hospital admissions.
 ► Cost; resource use and utility outcomes to inform the 
economic model.




The primary outcomes of the study are exacerbations and 
loss of/change in asthma control measured by a validated 
test.
1. Exacerbations are defined as in ERS/ATS,24 namely 
‘events characterised by a change from the patient’s previous 
status’. We will define exacerbations as every event 
requiring the use of OCS, the need for unscheduled 
visits with general practitioners (GPs) or at the emer-
gency department (ED) and hospitalisation.
2. Based on the definition reported in ERS/ATS,24 asth-
ma control corresponds to ‘the extent to which the various 
manifestations of asthma have been reduced or removed by 
treatment’.
Exacerbations are expected to be an individual- level 
numerical variable (binary, ordinal or count) or an 
individual- level time- to- event variable. Asthma control 
is expected to be an individual- level numerical variable 
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(categorical) and will be measured by a validated test (eg, 
ACT,25 ACQ,26–29 etc). Table 2 represents a possible cate-
gorisation for asthma control outcome based on ACT/
ACQ Scores. A standardisation method coherently to 
ACT and ACQ will be applied for other kinds of tests. 
After consultation with clinicians, we will decide if, for 
this outcome variable, it is worthier to consider the full 
longitudinal profile (multiple measurements) or to estab-
lish a clinically relevant timepoint.
Secondary outcomes
The secondary outcomes of the study are as follows.
1. Symptoms/symptom score: The mode to report symp-
toms or symptom score may be different across studies. 
We will distinguish between daytime and night- time 
symptoms, whatever they are, also considering their 
intensity.
2. QoL: It may have been measured differently across the 
studies. We will use the most frequent scale as a model 
to transform the remaining data using, for example, 
established conversion tables.
3. Mortality: This variable may be reported in different 
ways across studies. It will always be converted to a bi-
nary variable.
4. Physiological measurements: FEV1 in L/s and PEFR%. 
After consulting clinicians, we will decide if consider-
ing the full longitudinal profile (multiple measures) or 
establishing a clinically relevant timepoint.
5. Adverse events: These may differ across the studies. 
We will consider relevant AEs, such as cardiac and 
neuropsychiatric disorders, infections, pneumonia, be-
havioural difficulty, growth and diabetes.
6. Hospital admissions: This variable may be reported in 
different ways across studies. We will look for evidence 
such as dates of hospitalisation, adverse events indicat-
ing admission occurred and variables directly report-
ing hospitalisation, between the randomisation visit 
and the end of the follow- up.
Economic outcomes
7. The primary economic outcome will be the incremen-
tal cost per QALY gained. This will be estimated from 
data on:
a. Hospital admissions.
b. Other items: resource use, costs, and utilities—these 
will be based on purposive searches of the economic 
and medical literature.
Risk of bias in individual studies
Two independent reviewers will use the Cochrane risk of 
bias tool34 to record risk of bias concerning randomisation 
method, allocation concealment, blinding, incomplete 
outcome data and selective reporting. Disagreements will 
be resolved through discussion with a third reviewer.
Data
Synthesis
For every separate outcome, we will create a NMA diagram 
displaying the number of studies and patients for each 
treatment comparison within the network.
We will fit a Bayesian hierarchical meta- analysis 
model—supplemented with aggregate data if necessary—
to synthesise the available IPD. We will thus estimate the 
relative treatment effect—odds ratio (OR) for categor-
ical data and difference in means for continuous data—
and credibility interval for every pairwise comparison 
based on direct evidence. We will assess the homogeneity 
assumption by comparing the deviance information crite-
rion (DIC) of fixed- effect and random- effect models and 
observing the between- trial variance. The forest plots, χ2 
test for heterogeneity and I2 statistic will be examined to 
assess the evidence of heterogeneity within each pairwise 
meta- analysis based on direct evidence.
We will conduct an NMA for every outcome within a 
Bayesian framework with the WinBUGS software with the 
goodness of fit assessed by calculating the posterior mean 
residual deviance with DIC used as a basis for model 
comparison. Correlation between treatment effects from 
multiarm trials will be appropriately accounted for. From 
the NMA, we can estimate the relative treatment effect 
for every pairwise comparison irrespective of they have 
been compared directly in an RCT as well as calculating 
the probability that each treatment is the best or worst 
for a given outcome. In random effects NMA models, we 
will check the conventional assumption that between- 
trial variance is the same for each comparison, by fitting 
pairwise models based on direct evidence and assessing 
whether the variance is similar for each comparison. If 
the assumption appears unrealistic, we will explore other 
variance structures for the NMA model.
In an NMA, the indirect comparisons are not protected 
by randomisation, as for direct comparisons. So, they may 
be affected by confounding due to differences among 
clinical trials.35 The validity of an NMA thus depends on 
the critical assumption of transitivity, namely to verify 
whether the probability of having been able to have given 
any of the treatment in the network to any patient in the 
Table 2 A possible categorisation of asthma control 
outcome based on ACT/ACQ Scores





















To be evaluated on an 
individual case by case 
basis
Note: if both ACT and ACQ are present, we will choose ACT as the 
best choice.
ACQ, asthma control questionnaire; ACT, asthma control test.
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network was equally likely.35 We will check this assumption 
by comparing the inclusion/exclusion criteria of trials to 
make a judgement about whether patients, trial proto-
cols, doses and administration procedures are similar in 
the modes that might modify treatment effect. We will 
use model fit and selection statistics to informally assess 
whether inconsistency is evident along with a formal anal-
ysis using a ‘node- splitting’ approach.36 37
We will explore potential patient- level characteristics 
that may modify treatment effects using hierarchical 
models with interaction effects between treatment and 
specific covariates. Initially, based on direct evidence 
and subsequently in an NMA of the IPD, with aggregate 
data if IPD is unavailable.38–41 The effect of covariates 
will be separated within and between trials. The under-
lying consistency assumption of these models will also be 
explored. Patient- level characteristics of interest include 
age, gender, ethnicity, eczema status, asthmatic pheno-
type, baseline PEFR% and asthma severity. A literature 
search will be conducted to identify any further potential 
characteristics to explore.
We will fit an NMA model to compare compounds 
within each class and separate models to compare the 
different classes of treatments. Furthermore, complex 
hierarchical models that account for both classes and 
compounds with covariate interactions will be explored.
We will undertake sensitivity analyses for investigating 
the impact of missing IPD at the level of results and 
conclusions of NMA and for exploring the robustness of 
results to different priors in the Bayesian analyses. If suffi-
cient data are available, sensitivity analyses that adjust for 
levels of adherence will be conducted to assess the robust-
ness of results obtained from the primary analysis on the 
ITT patients.
Metabias(es)
To minimise the impact of selective outcome reporting, 
we will include all RCTs meeting our inclusion criteria 
irrespective of the outcome(s) reported in the publica-
tion. For analyses containing 10 or more trials—due to 
the low power of the assessments for analyses containing 
small numbers of trials—we will investigate publication 
bias (and other selection bias/small study effects) by 
using funnel plots and appropriate statistical tests for 
funnel plot asymmetry.
Confidence in cumulative evidence
We will assess the quality of evidence for all outcomes 
across the domains of risk of bias, consistency, directness, 
precision and publication bias according to Grading of 
Recommendations Assessment, Development and Evalu-
ation (Grade).
Economic analysis
The economic analysis will be conducted using standard 
methods,42 based on the most robust data available and 
reported according to the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) statement.43 
Cost- effectiveness will be estimated from the perspec-
tive of the NHS and Personal Social Services in line with 
NICE guidance44 and based on an economic model that 
considers health outcomes, resource use, costs and health 
utilities to estimate the incremental cost per QALY gained 
of each treatment. This analysis will not consider missed 
school or work.
The parameters needed to populate the models will 
include outcomes estimated by the NMA of the IPD (eg, 
efficacy and safety parameters) and other parameters (eg, 
utilities, resource use and the long- term costs of care) 
that will require searching of evidence beyond the studies 
included in the NMA. These will be sourced from a purpo-
sive review of the literature and by using specialist data-
bases (eg, NHS Economic Evaluation Database (EED) for 
resource use parameters and the Tufts CEA registry for 
utility parameters) where necessary. Unit cost data will be 
derived from standard national sources (eg, NHS refer-
ence costs45 and the British National Formulary46).
A Markov model will be necessary for longer- term 
extrapolation of costs and outcomes, to allow for any 
differential impacts of treatments over time and for 
transition of patients among the five steps of treat-
ment.47 Results of the NMA will be converted to transi-
tion probabilities based on standard methods.48 49 The 
model will evaluate costs and outcomes over the life-
time of the patient cohorts: costs and benefits in future 
years will be discounted at an annual rate of 3.5% and 
varied between 0% and 6% in sensitivity analysis. Results 
from the model will be reported as incremental cost 
per QALY gained incremental cost- effectiveness ratios 
(ICERs) and compared with the NICE threshold range of 
£20 000–£30 000 per QALY.
Uncertainties in all parameter inputs will be accounted 
for in the analysis by including parametric distributions 
for each point estimate, supplemented by expert opinion, 
where the evidence is not sufficiently detailed. This will 
enable probabilistic sensitivity analyses to be performed 
based on sampling from distributions using Monte Carlo 
simulation. The NMA estimates relative effects jointly, 
and the full joint distribution of these effects will be used 
in the economic model in order to preserve correlation.50 
Uncertainty in the optimally cost- effective treatment 
will be represented by cost- effectiveness acceptability 
curves (CEACs),51 which present the probability that 
each drug is the most cost- effective at a given threshold 
of cost- effectiveness. Where the IPD- NMA indicates that 
patient characteristics modify treatment effects, a strat-
ified approach will be used to assess cost- effectiveness 
in particular patient subgroup(s). Standard techniques 
(eg, extreme value scenarios) will be used to ensure the 
internal validity of the model.
We will conduct a value of information analysis to 
inform future research priorities, for example, whether 
more short- term efficacy trials are needed, or more long- 
term follow- up, or more data on the utilities, or costs to 
reduce decision uncertainty.52 The expected value of 
perfect information (EVPI) and the expected value of 
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perfect parameter information (EVPPI) will be calculated 
on both per- patient and population levels using the Shef-
field accelerated value of information approximation53 to 
facilitate computation effort.
ETHICS AND DISSEMINATION
The Committee on Research Ethics, University of Liver-
pool, has confirmed that ethics review is not required. 
The dissemination plan consists of publishing the results 
in an open- access medical journal, a plain- language 
summary available for parents and children, dissemina-
tion via local, national and international meetings and 
conferences and the press offices of our HEIs. A synopsis 
of results will be disseminated to NICE and BTS/SIGN as 
highly relevant to future clinical guideline updates.
Patient and public involvement
The EINSTEIN protocol has been developed in consul-
tation with children with asthma and their parents and 
with NHS clinicians who routinely care for children with 
uncontrolled asthma in NHS settings. First, we have 
sought advice on our proposal and the lay summary from 
five families, including two children, who attended our 
asthma clinic at Alder Hey. Second, the outcomes chosen 
in our review have been selected from a core outcome 
set which were agreed as important by clinicians and 
patients.21 This earlier work was heavily influenced by 
patients and, in particular, highlighted the importance 
to parents of including mortality and long- term AEs as 
outcomes. Finally, we consulted an Alder Hey’s patient 
advisory group, comprising children with asthma and 
their parents and asked them to comment specifically on 
the lay summary and choice of outcomes in the review 
project. We will consult with the patient group towards 
the end of the project to help prepare a patient- friendly 
podcast or leaflet that could be shared on asthma websites 
and in clinics. We will share our findings at important 
international meetings and in medical journals, and we 
will make sure that this process reflects issues that are 
important to children and families. Our patient represen-
tative (OF) will help to coordinate the group of patients 
and parents, along with physicians involved. Patients will 
not be involved in the recruitment to and conduct of the 
study.
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